Publications by authors named "Atila Yıldırım"
Effect of Ki-67 proliferation index on survival in large cell neuroendocrine carcinoma of the lung.
Rev Assoc Med Bras (1992)
September 2024
Article Synopsis
- The study explores the survival rates of patients with large cell neuroendocrine carcinoma of the lung, focusing on the Ki-67 proliferation index and other clinical characteristics.
- The research involved 38 patients and found that factors like age, tumor location, metastasis at diagnosis, and treatment received could impact overall survival rates, though not significantly statistically.
- It concludes that identifying specific subgroups with lower survival rates could aid in patient prognosis, but larger studies are necessary for more definitive insights.
Objective: To evaluate the impact of CDK4/6 inhibitors on erythrocyte mean corpuscular volume (MCV) change and its possible correlation with progression-free survival (PFS) and overall survival (OS).
Study Design: Observational study. Place and Duration of the Study: Department of Medical Oncology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkiye, between January 2020 and 2023.
Objective: To investigate the outcomes of regorafenib treatment in refractory metastatic colorectal cancer (mCRC) patients by primary tumour sidedness, the effects of previously targeted therapies, RAS status and inflammatory markers.
Study Design: Observational study. Place and Duration of the Study: Department of Medical Oncology, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey, between January 2012 and September 2020.
Aim: To compare survival outcomes, response rates, and adverse events (AEs) in proton pump inhibitor (PPI) user and non-user patients with metastatic colorectal cancer (mCRC) treated with regorafenib.
Methods: We included 272 patients with mCRC treated with regorafenib in this study. Patients were divided into two categories according to their status of PPI use.
Objective: To investigate whether albumin-bilirubin score can be used as a prognostic marker in pancreatic cancer patients post-surgery.
Methods: The retrospective study was conducted at the Medical Oncology Clinic, Karadeniz Technical University, Trabzon, Turkey, and comprised data from 2010 to 2018 of pancreatic cancer patients who had undergone distal pancreatectomy or pancreaticoduodenectomy and were followed up for 3 years. Preoperative and postoperative serum albumin, carcinoembryonic antigen, carbohydrate antigen 19-9, bilirubin, neutrophil:lymphocyte ratio and platelet:lymphocyte ratio were compared as inflammation markers, while albumin-bilirubin scores were calculated using the equation linear predictor.
Hearing Loss After the First Low Dose Administration of Cisplatin.
J Coll Physicians Surg Pak
September 2022
Cisplatin is commonly used antineoplastic drug that is effective against different types of tumours. Nephrotoxicity, neurotoxicity, and ototoxicity constitute the main dose-limiting side effects of the drug. We present a case of sensorineural hearing loss after the first low dose of cisplatin.
View Article and Find Full Text PDF